Researchers found a five-marker panel that distinguished cerebral amyloid angiopathy, a major driver of brain swelling and bleeding associated with anti-amyloid therapies. Researchers at Banner Sun Health Research Institute have identified a blood-based biomarker panel that may identify Alzheimer’s disease patients at increased risk for brain swelling or bleeding associated with new anti-amyloid therapies. The study, published in Acta Neuropatho…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.